373 related articles for article (PubMed ID: 18451243)
1. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study.
Berthold DR; Pond GR; Roessner M; de Wit R; Eisenberger M; Tannock AI;
Clin Cancer Res; 2008 May; 14(9):2763-7. PubMed ID: 18451243
[TBL] [Abstract][Full Text] [Related]
2. The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
Saad F; Ruether D; Ernst S; North S; Cheng T; Perrotte P; Karakiewicz P; Winquist E;
BJU Int; 2008 Aug; 102(5):551-5. PubMed ID: 18510661
[TBL] [Abstract][Full Text] [Related]
3. The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer.
Berry WR
Urology; 2005 Jun; 65(6 Suppl):2-7. PubMed ID: 15939076
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
Zhang HL; Ye DW; Yao XD; Dai B; Zhang SL; Shen YJ; Zhu Y; Zhang W
Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847
[TBL] [Abstract][Full Text] [Related]
5. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.
Van Poppel H
Can J Urol; 2005 Feb; 12 Suppl 1():81-5. PubMed ID: 15780173
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.
Armstrong AJ; Garrett-Mayer E; Ou Yang YC; Carducci MA; Tannock I; de Wit R; Eisenberger M
J Clin Oncol; 2007 Sep; 25(25):3965-70. PubMed ID: 17761981
[TBL] [Abstract][Full Text] [Related]
7. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.
Berthold DR; Pond GR; Soban F; de Wit R; Eisenberger M; Tannock IF
J Clin Oncol; 2008 Jan; 26(2):242-5. PubMed ID: 18182665
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Tannock IF; de Wit R; Berry WR; Horti J; Pluzanska A; Chi KN; Oudard S; Théodore C; James ND; Turesson I; Rosenthal MA; Eisenberger MA;
N Engl J Med; 2004 Oct; 351(15):1502-12. PubMed ID: 15470213
[TBL] [Abstract][Full Text] [Related]
10. What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?
Oudard S; Banu E; Medioni J; Scotte F; Banu A; Levy E; Wasserman J; Kacso G; Andrieu JM
BJU Int; 2009 Jun; 103(12):1641-6. PubMed ID: 19210673
[TBL] [Abstract][Full Text] [Related]
11. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.
Machiels JP; Mazzeo F; Clausse M; Filleul B; Marcelis L; Honhon B; D'Hondt L; Dopchie C; Verschaeve V; Duck L; Verhoeven D; Jousten P; Bonny MA; Moxhon AM; Tombal B; Kerger J
J Clin Oncol; 2008 Nov; 26(32):5261-8. PubMed ID: 18794543
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
13. Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice.
Dowling AJ; Czaykowski PM; Krahn MD; Moore MJ; Tannock IF
J Urol; 2000 May; 163(5):1481-5. PubMed ID: 10751862
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Petrylak DP; Tangen CM; Hussain MH; Lara PN; Jones JA; Taplin ME; Burch PA; Berry D; Moinpour C; Kohli M; Benson MC; Small EJ; Raghavan D; Crawford ED
N Engl J Med; 2004 Oct; 351(15):1513-20. PubMed ID: 15470214
[TBL] [Abstract][Full Text] [Related]
15. Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma.
Gravis G; Bladou F; Salem N; Macquart-Moulin G; Serment G; Camerlo J; Genre D; Bardou VJ; Maraninchi D; Viens P
Cancer; 2003 Oct; 98(8):1627-34. PubMed ID: 14534878
[TBL] [Abstract][Full Text] [Related]
16. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
Rosenberg JE; Weinberg VK; Kelly WK; Michaelson D; Hussain MH; Wilding G; Gross M; Hutcheon D; Small EJ
Cancer; 2007 Aug; 110(3):556-63. PubMed ID: 17577218
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases.
Raghavan D; Brandes LJ; Klapp K; Snyder T; Styles E; Tsao-Wei D; Lieskovsky G; Quinn DI; Ramsey EW
J Urol; 2005 Nov; 174(5):1808-13; discussion 1813. PubMed ID: 16217292
[TBL] [Abstract][Full Text] [Related]
18. Three-weekly docetaxel with prednisone is feasible for Japanese patients with hormone-refractory prostate cancer: a retrospective comparative study with weekly docetaxel alone.
Shimazui T; Kawai K; Miyanaga N; Kojima T; Sekido N; Hinotsu S; Oikawa T; Joraku A; Akaza H
Jpn J Clin Oncol; 2007 Aug; 37(8):603-8. PubMed ID: 17673473
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
Saad F; Hotte S; North S; Eigl B; Chi K; Czaykowski P; Wood L; Pollak M; Berry S; Lattouf JB; Mukherjee SD; Gleave M; Winquist E;
Clin Cancer Res; 2011 Sep; 17(17):5765-73. PubMed ID: 21788353
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
Rago RP; Einstein A; Lush R; Beer TM; Ko YJ; Henner WD; Bubley G; Merica EA; Garg V; Ette E; Harding MW; Dalton WS
Cancer Chemother Pharmacol; 2003 Apr; 51(4):297-305. PubMed ID: 12721757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
